N n 1 2005 ...

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1999 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known Application Number 09/471,040 INFORMATION DISCLOSURE Filing Date 12/23/1999 STATEMENT BY APPLICANT TILSTAM, Ulf et al First Named Inventor Group Art Unit 1623 (use as many sheets às necessary) OWENS, Jr., Howard V. **Examiner Name** Sheet SCH-1615-D01 of Attorney Docket Number

	U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No.¹		nd Code² (known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
HO	A1	5,110,919		Blumbergs	05-05-1992	
No	A2	3,703,507		Haskell, T. H. et al.	11-21-1972	
	<u> </u>					
					· .	
····						
		·				
				•		

		Foreign Patent Document				Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner Initials*	Cite No.1	Office ³	Number ⁴	Kind Code ^s (If known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T⁴
	B1	SDE	195 43 052 -	Λ1-	Schering AG	05-07-1997	-	
110	B2	wo	91/08215		Ash Stevens, Inc.	06-13-1991		
40	B3	wo	94/12514		Schering AG	06-09-1994		
#0	B4	wo	97/18211		Archimica S.P.A.	05-22-1997		
٠	B6-	EP.	1 047 704	B1	Schering AG	11-30-1998		X
				 				

Examiner Signature Date Considered 6-10-05

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

PTO/SB/08A (08-00)

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

Complete if Known				
Application Number	09/471,040			
Filing Date	12/23/1999			
First Named Inventor	TILSTAM, Ulf et al.			
Group Art Unit	1623			
Examiner Name	OWENS, Jr., Howard V.			
Attorney Docket Number	SCH-1615-D01			

Examiner Initials* Cite No.¹ Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book magazine, cumils, serial, spring, serial, serial, spring, serial, spring, serial, seri			NON PATENT LITERATURE DOCUMENTS	
Mayne Pharma Pty, Ltd., Date of Mention 01/29/2003. C2 Declaration of Donald Corcoran, dated 10/27/2003. Letter from Alltech Association Australia Pty, Ltd., dated 10/22/2003 with declaration attached from Dr. Phillip J. Anevski, dated 10/23/2003. C3 Letter from Boult Wade Tennant dated 10/29/2003. C4 Letter from Boult Wade Tennant dated 10/29/2003. C5 The Nucleic Acids Chemistry and Biology, Volume 1, 1955, chapter 6, pages 211 - 241. Exhibit C, Fludarabine Phosphate >99.5% Pure After Dowex 1X4 Column, 7/24/2003, with attached, Waldo E. Cohn, The Anion-Exchange Separation of Ribonucleotides, 72 J. Am. Chem. Soc., pp. 1471 - 1478 (1950) Waldo E. Cohn, Methods of Isolation and Characterization of Mono and Polynucleotides by Ion Exchange Chromatography, 107 Methods in Enzymology, pp. 724 - 743 (1967). C8 In the House of Lords, Biogen Inc. v. Medeva PLC, dated October 31, 1996, pages 1 - 54. Henry Herbert Cobb III, Stability of Fludarabine Phosphate, Pentostatin, and Amsacrine in Commonly Used Infusion Solutions and After Filtration, and Osmolality of Various Constituted Chemotherapeutic Agents, pp. 20 - 48 (1995). C10 Boards of Appeal of The European Patent Office, Decision, Previously Presented. 20 - 48, Case No. T 0990/96 - 3.3.1. (02/12/1998) C11 The MERCK Index, Twelfth Edition, 1996, **Fludarabine** C12 Official Monographs, USP 26, Fludarabine Phosphate, pages 3096 - 3097 (1996). C13 U-9: Schering's Reply C14 Notice of Opposition to European Patent No. EP 1047704, App. No. 98965703.6, by Curtis, Phillip Anthony, 11/11/2003. C15 Inc., Date of Mention 1/29/2003. EP-B-1047704 Opposition by SICOR Inc., in European Patent No. 1047704, App. No. 98965703.6, Experimental Report, dated 10/29/2003.		Cite No.1		T²
Letter from Alltech Association Australia Pty, Ltd., dated 10/22/2003 with declaration attached from Dr. Phillip J. Anevski, dated 10/23/2003. C4 Letter from Boult Wade Tennant dated 10/29/2003. C5 The Nucleic Acids Chemistry and Biology, Volume 1, 1955, chapter 6, pages 211 - 241. Exhibit C, Fludarabine Phosphate > 99.5% Pure After Dowex 1X4 Column, 7/24/2003, with attached, Waldo E. Cohn, The Anion-Exchange Separation of Ribonucleotides, 72 J. Am. Chem. Soc., pp. 1471 - 1478 (1950) Waldo E. Cohn, Methods of Isolation and Characterization of Mono and Polynucleotides by lon Exchange Chromatography, 107 Methods in Enzymology, pp. 724 - 743 (1967). C8 In the House of Lords, Biogen Inc. v. Medeva PLC, dated October 31, 1996, pages 1 - 54. Henry Herbert Cobb III, Stability of Fludarabine Phosphate, Pentostatin, and Amsacrine in Commonly Used Infusion Solutions and After Filtration, and Osmolality of Various Constituted Chemotherapeutic Agents, pp. 20 - 48 (1995). C10 Boards of Appeal of The European Patent Office, Decision, Previously Presented. 20 - 48, Case No. T 0990/96 - 3.3.1. (02/12/1998) C11 The MERCK Index, Twelfth Edition, 1996, Fludarabine C12 Official Monographs, USP 26, Fludarabine Phosphate, pages 3096 - 3097 (1996). C13 U.S. Schering's Reply C14 Notice of Opposition to European Patent No. EP 1047704, App. No. 98965703.6, by Curtis, Phillip Anthony, 11/11/2003. C15 Notice of Opposition to European Patent No. EP 1047704, App. No. 98965703.6, by Sicor, Inc., Date of Mention 1/29/2003.	Ao	C1	1	
attached from Dr. Phillip J. Anevski, dated 10/23/2003. C4 Letter from Boult Wade Tennant dated 10/29/2003. C5 The Nucleic Acids Chemistry and Biology, Volume 1, 1955, chapter 6, pages 211 - 241. Exhibit C, Fludarabine Phosphate >99.5% Pure After Dowex 1X4 Column, 7/24/2003, with attached, Waldo E. Cohn, The Anion-Exchange Separation of Ribonucleotides, 72 J. Am. Chem. Soc., pp. 1471 - 1478 (1950) C7 Waldo E. Cohn, Methods of Isolation and Characterization of Mono and Polynucleotides by lon Exchange Chromatography, 107 Methods in Enzymology, pp. 724 - 743 (1967). C8 In the House of Lords, Biogen Inc. v. Medeva PLC, dated October 31, 1996, pages 1 - 54. Henry Herbert Cobb III, Stability of Fludarabine Phosphate, Pentostatin, and Amsacrine in Commonly Used Infusion Solutions and After Filtration, and Osmolality of Various Constituted Chemotherapeutic Agents, pp. 20 - 48 (1995). C10 Boards of Appeal of The European Patent Office, Decision, Previously Presented. 20 - 48, Case No. T 0990/96 - 3.3.1. (02/12/1998) C11 The MERCK Index, Twelfth Edition, 1996, Fludarabine Phosphate, pages 3096 - 3097 (1996). C13 Official Monographs, USP 26, Fludarabine Phosphate, pages 3096 - 3097 (1996). C14 Notice of Opposition to European Patent No. EP 1047704, App. No. 98965703.6, by Curtis, Phillip Anthony, 11/11/2003. C15 Notice of Opposition to European Patent No. EP 1047704, App. No 98965703.6, by Sicor, Inc., Date of Mention 1/29/2003. C16 EP-B-1047704 Opposition by SICOR Inc., in European Patent No. 1047704, App. No. 98965703.6, Experimental Report, dated 10/29/2003.	Ho	C2	Declaration of Donald Corcoran, dated 10/27/2003.	
The Nucleic Acids Chemistry and Biology, Volume 1, 1955, chapter 6, pages 211 - 241. Exhibit C, Fludarabine Phosphate >99.5% Pure After Dowex 1X4 Column, 7/24/2003, with attached, Waldo E. Cohn, The Anion-Exchange Separation of Ribonucleotides, 72 J. Am. Chem. Soc., pp. 1471 - 1478 (1950) Waldo E. Cohn, Methods of Isolation and Characterization of Mono and Polynucleotides by lon Exchange Chromatography, 107 Methods in Enzymology, pp. 724 - 743 (1967). C8 In the House of Lords, Biogen Inc. v. Medeva PLC, dated October 31, 1996, pages 1 - 54. Henry Herbert Cobb III, Stability of Fludarabine Phosphate, Pentostatin, and Amsacrine in Commonly Used Infusion Solutions and After Filtration, and Osmolality of Various Constituted Chemotherapeutic Agents, pp. 20 - 48 (1995). C10 Boards of Appeal of The European Patent Office, Decision, Previously Presented. 20 - 48, Case No. T 0990/96 - 3.3.1. (02/12/1998) C11 The MERCK Index, Twelfth Edition, 1996, Fludarabine C12 Official Monographs, USP 26, Fludarabine Phosphate, pages 3096 - 3097 (1996). C13 U.S. Schering's Reply C14 Notice of Opposition to European Patent No. EP 1047704, App. No. 98965703.6, by Curtis. Phillip Anthony, 11/11/2003. C15 Notice of Opposition to European Patent No. EP 1047704, App. No. 98965703.6, by Sicor, Inc., Date of Mention 1/29/2003. C16 EP-B-1047704 Opposition by SICOR Inc., in European Patent No. 1047704, App. No. 98965703.6, Experimental Report, dated 10/29/2003.	#0	СЗ		
Exhibit C, Fludarabine Phosphate >99.5% Pure After Dowex 1X4 Column, 7/24/2003, with attached, Waldo E. Cohn, The Anion-Exchange Separation of Ribonucleotides, 72 J. Am. Chem. Soc., pp. 1471 - 1478 (1950) C7 Waldo E. Cohn, Methods of Isolation and Characterization of Mono and Polynucleotides by lon Exchange Chromatography, 107 Methods in Enzymology, pp. 724 - 743 (1967). C8 In the House of Lords, Biogen Inc. v. Medeva PLC, dated October 31, 1996, pages 1 - 54. Henry Herbert Cobb III, Stability of Fludarabine Phosphate, Pentostatin, and Amsacrine in Commonly Used Infusion Solutions and After Filtration, and Osmolality of Various Constituted Chemotherapeutic Agents, pp. 20 - 48 (1995). C10 Boards of Appeal of The European Patent Office, Decision, Previously Presented. 20 - 48, Case No. T 0990/96 - 3.3.1. (02/12/1998) C11 The MERCK Index, Twelfth Edition, 1996, Fludarabine C12 Official Monographs, USP 26, Fludarabine Phosphate, pages 3096 - 3097 (1996). C13 U.S. Schering's Reply C14 Notice of Opposition to European Patent No. EP 1047704, App. No. 98965703.6, by Curtis, Phillip Anthony, 11/11/2003. C15 Notice of Opposition to European Patent No. EP 1047704, App. No 98965703.6, by Sicor, Inc., Date of Mention 1/29/2003. C16 EP-B-1047704 Opposition by SICOR Inc., in European Patent No. 1047704, App. No. 98965703.6, Experimental Report, dated 10/29/2003.	10	C4	Letter from Boult Wade Tennant dated 10/29/2003.	
C6 attached, Waldo E. Cohn, The Anion-Exchange Separation of Ribonucleotides, 72 J. Am. Chem. Soc., pp. 1471 - 1478 (1950) C7 Waldo E. Cohn, Methods of Isolation and Characterization of Mono and Polynucleotides by Ion Exchange Chromatography, 107 Methods in Enzymology, pp. 724 - 743 (1967). C8 In the House of Lords, Biogen Inc. v. Medeva PLC, dated October 31, 1996, pages 1 - 54. Henry Herbert Cobb III, Stability of Fludarabine Phosphate, Pentostatin, and Amsacrine in Commonly Used Infusion Solutions and After Filtration, and Osmolality of Various Constituted Chemotherapeutic Agents, pp. 20 - 48 (1995). C10 Boards of Appeal of The European Patent Office, Decision, Previously Presented. 20 - 48, Case No. T 0990/96 - 3.3.1. (02/12/1998) C11 The MERCK Index, Twelfth Edition, 1996, Fludarabine C12 Official Monographs, USP 26, Fludarabine Phosphate, pages 3096 - 3097 (1996). C13 U.S. Schering's Reply C14 Notice of Opposition to European Patent No. EP 1047704, App. No. 98965703.6, by Curtis, Phillip Anthony, 11/11/2003. C15 Notice of Opposition to European Patent No. EP 1047704, App. No 98965703.6, by Sicor, Inc., Date of Mention 1/29/2003. C16 EP-B-1047704 Opposition by SICOR Inc., in European Patent No. 1047704, App. No. 98965703.6, Experimental Report, dated 10/29/2003.	No	C5	The Nucleic Acids Chemistry and Biology, Volume 1, 1955, chapter 6, pages 211 - 241.	
lon Exchange Chromatography, 107 Methods in Enzymology, pp. 724 - 743 (1967). C8 In the House of Lords, Biogen Inc. v. Medeva PLC, dated October 31, 1996, pages 1 - 54. Henry Herbert Cobb III, Stability of Fludarabine Phosphate, Pentostatin, and Amsacrine in Commonly Used Infusion Solutions and After Filtration, and Osmolality of Various Constituted Chemotherapeutic Agents, pp. 20 - 48 (1995). C10 Boards of Appeal of The European Patent Office, Decision, Previously Presented. 20 - 48, Case No. T 0990/96 - 3.3.1. (02/12/1998) C11 The MERCK Index, Twelfth Edition, 1996. Fludarabine C12 Official Monographs, USP 26, Fludarabine Phosphate, pages 3096 - 3097 (1996). C13 U.S. Schering's Reply C14 Notice of Opposition to European Patent No. EP 1047704, App. No. 98965703.6, by Curtis, Phillip Anthony, 11/11/2003. C15 Notice of Opposition to European Patent No. EP 1047704, App. No 98965703.6, by Sicor, Inc., Date of Mention 1/29/2003. C16 EP-B-1047704 Opposition by SICOR Inc., in European Patent No. 1047704, App. No. 98965703.6, Experimental Report, dated 10/29/2003.	Ho	C6	attached, Waldo E. Cohn, The Anion-Exchange Separation of Ribonucleotides, 72 J. Am.	
Henry Herbert Cobb III, Stability of Fludarabine Phosphate, Pentostatin, and Amsacrine in Commonly Used Infusion Solutions and After Filtration, and Osmolality of Various Constituted Chemotherapeutic Agents, pp. 20 - 48 (1995). C10 Boards of Appeal of The European Patent Office, Decision, Previously Presented. 20 - 48, Case No. T 0990/96 - 3.3.1. (02/12/1998) C11 The MERCK Index, Twelfth Edition, 1996, Fludarabine C12 Official Monographs, USP 26, Fludarabine Phosphate, pages 3096 - 3097 (1996). C13 U.S. Schering's Reply C14 Notice of Opposition to European Patent No. EP 1047704, App. No. 98965703.6, by Curtis, Phillip Anthony, 11/11/2003. C15 Notice of Opposition to European Patent No. EP 1047704, App. No 98965703.6, by Sicor, Inc., Date of Mention 1/29/2003. C16 EP-B-1047704 Opposition by SICOR Inc., in European Patent No. 1047704, App. No. 98965703.6, Experimental Report, dated 10/29/2003.	Ag	C7		
C9 Commonly Used Infusion Solutions and After Filtration, and Osmolality of Various Constituted Chemotherapeutic Agents, pp. 20 - 48 (1995). C10 Boards of Appeal of The European Patent Office, Decision, Previously Presented. 20 - 48, Case No. T 0990/96 - 3.3.1. (02/12/1998) C11 The MERCK Index, Twelfth Edition, 1996, Fludgrabine C12 Official Monographs, USP 26, Fludarabine Phosphate, pages 3096 - 3097 (1996). C13 U.S. Schering's Reply C14 Notice of Opposition to European Patent No. EP 1047704, App. No. 98965703.6, by Curtis, Phillip Anthony, 11/11/2003. C15 Notice of Opposition to European Patent No. EP 1047704, App. No 98965703.6, by Sicor, Inc., Date of Mention 1/29/2003. C16 EP-B-1047704 Opposition by SICOR Inc., in European Patent No. 1047704, App. No. 98965703.6, Experimental Report, dated 10/29/2003.	No	C8	In the House of Lords, Biogen Inc. v. Medeva PLC, dated October 31, 1996, pages 1 - 54.	
Case No. T 0990/96 - 3.3.1. (02/12/1998) Ho C11 The MERCK Index, Twelfth Edition, 1996, Fludarabine C12 Official Monographs, USP 26, Fludarabine Phosphate, pages 3096 - 3097 (1996). C13 U.S. Schering's Reply C14 Notice of Opposition to European Patent No. EP 1047704, App. No. 98965703.6, by Curtis, Phillip Anthony, 11/11/2003. C15 Notice of Opposition to European Patent No. EP 1047704, App. No 98965703.6, by Sicor, Inc., Date of Mention 1/29/2003. C16 EP-B-1047704 Opposition by SICOR Inc., in European Patent No. 1047704, App. No. 98965703.6, Experimental Report, dated 10/29/2003.	Ao	.C9	Commonly Used Infusion Solutions and After Filtration, and Osmolality of Various	
C12 Official Monographs, USP 26, Fludarabine Phosphate, pages 3096 - 3097 (1996). C13 U.S. Schering's Reply. C14 Notice of Opposition to European Patent No. EP 1047704, App. No. 98965703.6, by Curtis, Phillip Anthony, 11/11/2003. C15 Notice of Opposition to European Patent No. EP 1047704, App. No 98965703.6, by Sicor, Inc., Date of Mention 1/29/2003. C16 EP-B-1047704 Opposition by SICOR Inc., in European Patent No. 1047704, App. No. 98965703.6, Experimental Report, dated 10/29/2003.	40	C10	Boards of Appeal of The European Patent Office, Decision, Previously Presented. 20 - 48, Case No. T 0990/96 - 3.3.1. (02/12/1998)	
C13 U.S. Schering's Reply C14 Notice of Opposition to European Patent No. EP 1047704, App. No. 98965703.6, by Curtis, Phillip Anthony, 11/11/2003. C15 Notice of Opposition to European Patent No. EP 1047704, App. No 98965703.6, by Sicor, Inc., Date of Mention 1/29/2003. C16 EP-B-1047704 Opposition by SICOR Inc., in European Patent No. 1047704, App. No. 98965703.6, Experimental Report, dated 10/29/2003.	Ho	C11	The MERCK Index, Twelfth Edition, 1996, Fludgrabine	
C14 Notice of Opposition to European Patent No. EP 1047704, App. No. 98965703.6, by Curtis, Phillip Anthony, 11/11/2003. C15 Notice of Opposition to European Patent No. EP 1047704, App. No 98965703.6, by Sicor, Inc., Date of Mention 1/29/2003. C16 EP-B-1047704 Opposition by SICOR Inc., in European Patent No. 1047704, App. No. 98965703.6, Experimental Report, dated 10/29/2003.	to	C12	Official Monographs, USP 26, Fludarabine Phosphate, pages 3096 - 3097 (1996).	
Phillip Anthony, 11/11/2003. C15 Notice of Opposition to European Patent No. EP 1047704, App. No 98965703.6, by Sicor, Inc., Date of Mention 1/29/2003. C16 EP-B-1047704 Opposition by SICOR Inc., in European Patent No. 1047704, App. No. 98965703.6, Experimental Report, dated 10/29/2003.		C13	U.S. Schering's Reply	,
Inc., Date of Mention 1/29/2003. EP-B-1047704 Opposition by SICOR Inc., in European Patent No. 1047704, App. No. 98965703.6, Experimental Report, dated 10/29/2003.	Do	C14		
98965703.6, Experimental Report, dated 10/29/2003.	Ho	C15		
C17 PCT Report for App. No. PCT/EP98/07651, dated 1/27/00.	Hυ	C16	EP-B-1047704 Opposition by SICOR Inc., in European Patent No. 1047704, App. No. 98965703.6, Experimental Report, dated 10/29/2003.	
	-	C17	PCT-Report for App. No. PCT/EP98/07651, dated 1/27/00.	

Examiner	1000	Date	la con com
Signature	Had Las	Considered	6-10.05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Abstanding, VA 22313-1450.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English tanguage Translation is attached.